BioTech Weekly
Weekly podcast on the recent advancements in the Biotechnology field.
BioTech Weekly
BioTech Weekly - Week 24 - Jun 9-15, 2025
•
Ernst
🚀 Biotech & Life Sciences Weekly Highlights 🌱
- Privacy Under Fire: 27 states and D.C. are suing 23andMe to stop the sale of personal genetic data without consent — as Regeneron eyes acquisition during bankruptcy proceedings.
- Organoid Innovation: Pluristyx launches the PluriForm™ Organoid Kit, dramatically cutting down organoid development timelines with ready-to-differentiate iPSCs.
- Funding Milestone: Genesys Capital closes its largest fund yet — Genesys Ventures IV LP — backing Canadian life sciences with strong investor confidence.
- Rare Disease Breakthroughs: Chiesi Group partners with Key2Brain AB to advance blood-brain barrier-crossing therapies for lysosomal storage disorders.
- Next-Gen Neurotherapeutics: Enveric Biosciences secures a patent for low-hallucinogenic neuroplastogens, opening new doors in psychiatric treatment.
🔍 Stay tuned — innovation is not slowing down!
Sources
- Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent
- Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
- Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
- Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB
- Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens
- Five BIO 2025 events you don’t want to miss
- Layoff Tracker: Gilead Cuts 36 Employees in California